The financials
Medpace Holdings, Inc. by the numbers
Medpace Holdings, Inc. (MEDP) reported revenue of $707M in Q2 2026 (quarter ended June 30, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $121M (17% of revenue). For the full year FY2025, revenue was $2.53B (+20% year on year) and net income $451M. Its largest product in 2026-Q1 was Metabolic at $238M, 34% of the disclosed total, just ahead of Oncology at 28%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $707M | $603M | +17% |
| Gross profit | $202M | $180M | +12% |
| Operating income | $147M | $126M | +16% |
| Net income | $121M | $90M | +34% |
| Diluted EPS | $4.25 | $3.10 | +37% |
| Product | Revenue | Share |
|---|---|---|
| Metabolic | $238M | 34% |
| Oncology | $201M | 28% |
| Other | $93M | 13% |
| Central Nervous System | $80M | 11% |
| Cardiology | $56M | 8.0% |
| Antiviral And Anti Infective | $38M | 5.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $706.6M (+7.1%)
Metabolic grew +60% year on yearCardiology -3.5% year on year
Segment Latestquarter on quarteryear on year
- Metabolic$237.6M$237.6MQoQ +19%year on year +60%+19%+60%
- Oncology$201.2M$201.2MQoQ +4.5%year on year +18%+4.5%+18%
- Other$93.3M$93.3MQoQ -12%year on year -2.6%-12%-2.6%
- Central Nervous System$80.2M$80.2MQoQ +22%year on year +46%+22%+46%
- Cardiology$56.3M$56.3MQoQ -5.4%year on year -3.5%-5.4%-3.5%
- Antiviral And Anti Infective$38.0M$38.0MQoQ +4.1%year on year +22%+4.1%+22%
Diagnostics & Research
Ranks #3 of 29 by Smart Score